Hepatic tumor response evaluation by MRI

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 721-733

  Lee, Chang Hee ^a,b   Braga, Larissa ^c   de Campos, Rafael O P ^a   Semelka, Richard C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Korea University College of Medicine   (South Korea)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cancer; Diffusion weighted MRI; Dynamic contrast enhanced MRI; Liver; MRI; MRS; Perfusion weighted MRI

Indexed keywords

CANCER; DIFFUSION-WEIGHTED MRI; DYNAMIC CONTRAST-ENHANCED MRI; MRS; PERFUSION-WEIGHTED MRI;

BIOMARKERS; CHEMOTHERAPY; DIAGNOSIS; DISEASES; IONIZING RADIATION; NONINVASIVE MEDICAL PROCEDURES; PLANNING; RADIOTHERAPY; TUMORS;

MAGNETIC RESONANCE IMAGING;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CONTRAST MEDIUM; CYTOTOXIC AGENT; FLUOROURACIL; GADOLINIUM BENZOYLOXYPROPIONICTETRAACETATE; GADOLINIUM ETHOXYBENZYL DIETHYLENETRIAMINEPENTAACETATE; GADOLINIUM PENTETATE DERIVATIVE; IODINATED CONTRAST MEDIUM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SORAFENIB; THALIDOMIDE; UNCLASSIFIED DRUG;

ABLATION THERAPY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOTHERAPY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYNAMIC CONTRAST ENHANCED MRI; FLUORINE NUCLEAR MAGNETIC RESONANCE; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MICROWAVE THERAPY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79960763903     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1637     Document Type: Review

References (109)

1. Braga L, Armao D, Azzazi ME, Semelka RC.Liver. InAbdominal-Pelvic MRI, 3rd edn. Semelka RC (ed).Wiley-Blackwell: Hoboken, NJ, 2010;45-454.
2. Braga L, Semelka RC, Pedro MS, de Barros N.Post-treatment malignant liver lesions. MR imaging.Magn. Reson. Imaging Clin. N. Am. 2002;10:53-73.
3. Sorensen AG.Magnetic resonance as a cancer imaging biomarker.J. Clin. Oncol. 2006;24:3274-3281.
4. Hylton N.Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.J. Clin. Oncol. 2006;24:3293-3298.
5. Braga L, Guller U, Semelka RC.Pre-, peri-, and posttreatment imaging of liver lesions.Radiol. Clin. North Am. 2005;43:915-927.
6. Van Beers BE, Vilgrain V.Biomarkers in abdominal imaging.Abdom. Imaging, 2009;34:663-667.
7. 19F MRS pharmacokinetic studies of 5-fluorouracil.NMR Biomed. 2007;20:128-140.
8. Kierans AS, Elazzazi M, Braga L, Leonardou P, Gerber DA, Burke C, Qureshi W, Kanematsu M, Semelka RC.Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response.Am. J. Roentgenol. 2010;194:523-529.
9. Semelka RC, Worawattanakul S, Kelekis NL, John G, Woosley JT, Graham M, Cance WG.Liver lesion detection, characterization, and effect on patient management: comparison of single-phase spiral CT and current MR techniques.J. Magn. Reson. Imaging, 1997;7:1040-1047.
10. Semelka RC, Martin DR, Balci C, Lance T.Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement.J. Magn. Reson. Imaging, 2001;13:397-401.
11. Yamashita Y, Mitsuzaki K, Yi T, Ogata I, Nishiharu T, Urata J, Takahashi M.Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver.Radiology, 1996;200:79-84.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.J. Natl. Cancer Inst. 2000;92:205-216.
13. Hamstra DA, Rehemtulla A, Ross BD.Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology.J. Clin. Oncol. 2007;25:4104-4109.
14. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J.Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?Cancer, 2009;115:616-623.
15. van Laarhoven HW, Punt CJ, Kamm YJ, Heerschap A.Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.Crit. Rev. Oncol. Hematol. 2005;56:321-343.
16. Smith JJ, Sorensen AG, Thrall JH.Biomarkers in imaging: realizing radiology's future.Radiology, 2003;227:633-638.
17. Rudin M.Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions.Eur. Radiol. 2007;17:2441-2457.
18. Stephen RM, Gillies RJ.Promise and progress for functional and molecular imaging of response to targeted therapies.Pharm. Res. 2007;24:1172-1185.
19. Ferrara N.Vascular endothelial growth factor: molecular and biological aspects.Curr. Top. Microbiol. Immunol. 1999;237:1-30.
20. Kanematsu M, Osada S, Amaoka N, Goshima S, Kondo H, Kato H, Nishibori H, Yokoyama R, Hoshi H, Moriyama N.Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver and correlation with MRI findings.Am. J. Roentgenol. 2005;184:832-841.
21. Bammer R.Basic principles of diffusion-weighted imaging.Eur. J. Radiol. 2003;45:169-184.
22. Koinuma M, Ohashi I, Hanafusa K, Shibuya H.Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis.J. Magn. Reson. Imaging, 2005;22:80-85.
23. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H.Diffusion-weighted single-shot echoplanar MR imaging for liver disease.Am. J. Roentgenol. 1999;173:393-398.
24. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y.Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients.Radiology, 2003;226:71-78.
25. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M.Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.J. Magn. Reson. Imaging, 1999;9:53-60.
26. Chenevert TL, McKeever PE, Ross BD.Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.Clin. Cancer Res. 1997;3:1457-1466.
27. Schaefer PW, Grant PE, Gonzalez RG.Diffusion-weighted MR imaging of the brain.Radiology, 2000;217:331-345.
28. Armitage PA, Schwindack C, Bastin ME, Whittle IR.Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging.Magn. Reson. Imaging, 2007;25:303-310.
29. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP.Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.J. Clin. Oncol. 2003;21:3955-3964.
30. van Laarhoven HW, Rijpkema M, Punt CJ, Ruers TJ, Hendriks JC, Barentsz JO, Heerschap A.Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases.J. Magn. Reson. Imaging, 2003;18:315-320.
31. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT.Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.Am. J. Roentgenol. 2004;183:713-719.
32. Zechmann CM, Woenne EC, Brix G, Radzwill N, Ilg M, Bachert P, Peschke P, Kirsch S, Kauczor HU, Delorme S, Semmler W, Kiessling F.Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors.Neoplasia, 2007;9:57-67.
33. Dixon RM.NMR studies of phospholipid metabolism in hepatic lymphoma.NMR Biomed. 1998;11:370-379.
34. Ruiz-Cabello J, Cohen JS.Phospholipid metabolites as indicators of cancer cell function.NMR Biomed. 1992;5:226-233.
35. Mukherji SK, Schiro S, Castillo M, Kwock L, Muller KE, Blackstock W, Proton MR.spectroscopy of squamous cell carcinoma of the extracranial head and neck: in vitro and in vivo studies.Am. J. Neuroradiol. 1997;18:1057-1072.
36. Schilling A, Gewiese B, Berger G, Boese-Landgraf J, Fobbe F, Stiller D, Gallkowski U, Wolf KJ.Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.Radiology, 1992;182:887-890.
37. Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC.Chemoembolization for hepatocellular carcinoma.J. Clin. Oncol. 1990;8:1108-1114.
38. Lang EK, Brown CL Jr.Colorectal metastases to the liver: selective chemoembolization.Radiology, 1993;189:417-422.
39. Wallace S, Carrasco CH, Charnsangavej C, Richli WR, Wright K, Gianturco C.Hepatic artery infusion and chemoembolization in the management of liver metastases.Cardiovasc. Intervent. Radiol. 1990;13:153-160.
40. Semelka RC, Worawattanakul S, Mauro MA, Bernard SA, Cance WG.Malignant hepatic tumors: changes on MRI after hepatic arterial chemoembolization - preliminary findings.J. Magn. Reson. Imaging, 1998;8:48-56.
41. Yu JS, Rofsky NM.Dynamic subtraction MR imaging of the liver: advantages and pitfalls.Am. J. Roentgenol. 2003;180:1351-1357.
42. Kim S, Mannelli L, Hajdu CH, Babb JS, Clark TW, Hecht EM, Taouli B.Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.J. Magn. Reson. Imaging, 2010;31:348-355.
43. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B.Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.Am. J. Roentgenol. 2009;193:1044-1052.
44. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, Landuyt W, Ni Y.Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.Radiology, 2005;237:492-499.
45. Deng J, Rhee TK, Sato KT, Salem R, Haines K, Paunesku T, Mulcahy MF, Miller FH, Omary RA, Larson AC.In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla.Invest. Radiol. 2006;41:410-414.
46. Youn BJ, Chung JW, Son KR, Kim HC, Jae HJ, Lee JM, Song IC, Kim IO, Park JH.Diffusion-weighted MR: therapeutic evaluation after chemoembolization of VX-2 carcinoma implanted in rabbit liver.Acad. Radiol. 2008;15:593-600.
47. Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, Onozuka M, Moriyama N.Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator?J. Magn. Reson. Imaging, 2008;27:834-839.
48. Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC.Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants - initial experience.Radiology, 2006;239:448-456.
49. Kuo YT, Li CW, Chen CY, Jao J, Wu DK, Liu GC.In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner.J. Magn. Reson. Imaging, 2004;19:598-604.
50. Murakami T, Nakamura H, Hori S, Tomoda K, Mitani T, Nakanishi K, Hashimoto T, Tsuda K, Kozuka T, Monden M, Wakasa K.Detection of viable tumor cells in hepatocellular carcinoma following transcatheter arterial chemoembolization with iodized oil. Pathologic correlation with dynamic turbo-FLASH MR imaging with Gd-DTPA.Acta Radiol. 1993;34:399-403.
51. Castrucci M, Sironi S, De Cobelli F, Salvioni M, Del Maschio A.Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization.Abdom. Imaging, 1996;21:488-494.
52. Ito K, Honjo K, Fujita T, Matsui M, Awaya H, Matsumoto T, Matsunaga N, Nakanishi T.Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology.J. Comput. Assist. Tomogr. 1995;19:198-203.
53. Holbrook RF, Koo K, Ryan JA.Resection of malignant primary liver tumors.Am. J. Surg. 1996;171:453-455.
54. Ishii H, Furuse J, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Nakachi K, Suzuki E, Yoshino M.Hepatectomy for hepatocellular carcinoma patients who meet the Milan criteria.Hepatogastroenterology, 2008;55:621-626.
55. Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ.Spectrum of CT findings after radiofrequency ablation of hepatic tumors.Radiographics, 2008;28:379-390 discussion 390-372.
56. Lorentzen T.A cooled needle electrode for radiofrequency tissue ablation: thermodynamic aspects of improved performance compared with conventional needle design.Acad. Radiol. 1996;3:556-563.
57. Organ LW.Electrophysiologic principles of radiofrequency lesion making.Appl. Neurophysiol. 1976;39:69-76.
58. de Baere T, Denys A, Wood BJ, Lassau N, Kardache M, Vilgrain V, Menu Y, Roche A.Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems.Am. J. Roentgenol. 2001;176:187-192.
59. Curley SA.Radiofrequency ablation of malignant liver tumors.Oncologist, 2001;6:14-23.
60. McGhana JP, Dodd GD 3rd.Radiofrequency ablation of the liver: current status.Am. J. Roentgenol. 2001;176:3-16.
61. Aschoff AJ, Merkle EM, Wong V, Zhang Q, Mendez MM, Duerk JL, Lewin JS.How does alteration of hepatic blood flow affect liver perfusion and radiofrequency-induced thermal lesion size in rabbit liver?J. Magn. Reson. Imaging, 2001;13:57-63.
62. Goldberg SN, Gazelle GS, Mueller PR.Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance.Am. J. Roentgenol. 2000;174:323-331.
63. Kuszyk BS, Boitnott JK, Choti MA, Bluemke DA, Sheth S, Magee CA, Horton KM, Eng J, Fishman EK.Local tumor recurrence following hepatic cryoablation: radiologic-histopathologic correlation in a rabbit model.Radiology, 2000;217:477-486.
64. Limanond P, Zimmerman P, Raman SS, Kadell BM, Lu DS.Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies.Am. J. Roentgenol. 2003;181:1635-1640.
65. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP.Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.Nature, 1995;375:577-581.
66. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S.Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma.Gut, 2001;48:87-96.
67. Ishikawa K, Mochida S, Mashiba S, Inao M, Matsui A, Ikeda H, Ohno A, Shibuya M, Fujiwara K.Expressions of vascular endothelial growth factor in nonparenchymal as well as parenchymal cells in rat liver after necrosis.Biochem. Biophys. Res. Commun. 1999;254:587-593.
68. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M, Kitagawa K.Benign and malignant nodules in cirrhotic livers: distinction based on blood supply.Radiology, 1991;178:493-497.
69. Cotran RS, Kumar V, Collins T, Robbins SL.Robbins Pathologic Basis of Disease, 6th edn.Saunders: Philadelphia, PA, 1999.
70. Rubin E, Farber JL.Pathology, 3rd edn.Lippincott-Raven: Philadelphia, PA, 1999.
71. Shweiki D, Itin A, Soffer D, Keshet E.Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.Nature, 1992;359:843-845.
72. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M.Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans.J. Hepatol. 2000;33:282-289.
73. Scarfo LM, Weller PF, Farber HW.Induction of endothelial cell cytoplasmic lipid bodies during hypoxia.Am. J. Physiol. Heart Circ. Physiol. 2001;280:H294-H301.
74. Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, Lee JH, Lim JH, Choo IW.Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT.Radiology, 2001;221:447-454.
75. Joseph FB, Baumgarten DA, Bernardino ME.Hepatocellular carcinoma: CT appearance after percutaneous ethanol ablation therapy.Work in progress. Radiology, 1993;186:553-556.
76. Mitsuzaki K, Yamashita Y, Nishiharu T, Sumi S, Matsukawa T, Takahashi M, Beppu T, Ogawa M.CT appearance of hepatic tumors after microwave coagulation therapy.Am. J. Roentgenol. 1998;171:1397-1403.
77. Schlund JF, Semelka RC, Kettritz U, Weeks SM, Kahlenberg M, Cance WG.Correlation of perfusion abnormalities on CTAP and immediate postintravenous gadolinium-enhanced gradient echo MRI.Abdom. Imaging, 1996;21:49-52.
78. Lencioni R, Cioni D, Bartolozzi C.Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results.Abdom. Imaging, 2001;26:345-360.
79. Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, Petrow P, Roche A, Sigal R.Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up.Radiology, 2002;223:255-262.
80. Matsukawa T, Yamashita Y, Arakawa A, Nishiharu T, Urata J, Murakami R, Takahashi M, Yoshimatsu S.Percutaneous microwave coagulation therapy in liver tumors. A 3-year experience.Acta Radiol. 1997;38:410-415.
81. Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA.Liver metastases from breast cancer: long-term survival after curative resection.Surgery, 2000;127:383-389.
82. Semelka RC, Worawattanakul S, Noone TC, Burdeny DA, Kelekis NL, Woosley JT, Lee JK.Chemotherapy-treated liver metastases mimicking hemangiomas on MR images.Abdom. Imaging, 1999;24:378-382.
83. Worawattanakul S, Semelka RC, Kelekis NL, Woosley JT.Angiosarcoma of the liver: MR imaging pre- and post-chemotherapy.Magn. Reson. Imaging, 1997;15:613-617.
84. Braga L, Semelka RC, Pietrobon R, Martin D, de Barros N, Guller U.Does hypervascularity of liver metastases as detected on MRI predict disease progression in breast cancer patients?Am. J. Roentgenol. 2004;182:1207-1213.
85. Padhani AR, Husband JE.Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies.Clin. Radiol. 2001;56:607-620.
86. Haran EF, Maretzek AF, Goldberg I, Horowitz A, Degani H.Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth.Cancer Res. 1994;54:5511-5514.
87. Ohtomo K, Itai Y, Yoshikawa K, Yashiro N, Kokubo T, Iio M.MR imaging of hepatoma treated by embolization.J. Comput. Assist. Tomogr. 1986;10:973-975.
88. De Santis M, Torricelli P, Cristani A, Cioni G, Montanari N, Sardini C, Ventura E, Romagnoli R.MRI of hepatocellular carcinoma before and after transcatheter chemoembolization.J. Comput. Assist. Tomogr. 1993;17:901-908.
89. Itai Y, Irie T.Metastatic liver tumor: circumferential versus wedge-shaped perilesional enhancement and quantitative image and pathologic correlation.Radiology, 2001;219:298-300.
90. Semelka RC, Hussain SM, Marcos HB, Woosley JT.Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings - initial observations.Radiology, 2000;215:89-94.
91. Arisawa Y, Sutanto-Ward E, Fortunato L, Sigurdson ER.Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: a regional antiangiogenic therapy.Ann. Surg. Oncol. 1995;2:114-120.
92. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Armao D, Vaidean G, Firat Z, Woosley JT.Angiogenesis in hepatocellular nodules: correlation of MR imaging and vascular endothelial growth factor.J. Magn. Reson. Imaging, 2004;20:426-434.
93. Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Boden K, Eriksson-Alm Y, Berg E, Fujii H, Kubo A, Blomqvist L.Radiologic measurements of tumor response to treatment: practical approaches and limitations.Radiographics, 2008;28:329-344.
94. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, Hermans R.Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.Radiology, 2005;234:756-764.
95. Folkman J.Tumor angiogenesis: therapeutic implications.N. Engl. J. Med. 1971;285:1182-1186.
96. Genetech Inc. Product Information of Avastin. [Internet]. Available at: [Accessed 1 March 2005].
97. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J.Sorafenib in advanced hepatocellular carcinoma.N. Engl. J. Med. 2008;359:378-390.
98. Hein PA, Eskey CJ, Dunn JF, Hug EB.Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.Am. J. Neuroradiol. 2004;25:201-209.
99. Baur A, Huber A, Arbogast S, Durr HR, Zysk S, Wendtner C, Deimling M, Reiser M.Diffusion-weighted imaging of tumor recurrences and posttherapeutical soft-tissue changes in humans.Eur. Radiol. 2001;11:828-833.
100. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD.Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.Proc. Natl. Acad. Sci. USA, 2005;102:5524-5529.
101. Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, Berger R, Glicksman A, Baram J, Orenstein A, Cohen JS, Tichler T.Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging.J. Clin. Oncol. 2003;21:1094-1100.
102. Mardor Y, Roth Y, Ochershvilli A, Spiegelmann R, Tichler T, Daniels D, Maier SE, Nissim O, Ram Z, Baram J, Orenstein A, Pfeffer R.Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI.Neoplasia, 2004;6:136-142.
103. Taouli B, Martin AJ, Qayyum A, Merriman RB, Vigneron D, Yeh BM, Coakley FV.Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers.Am. J. Roentgenol. 2004;183:677-680.
104. Koh DM, Scurr E, Collins DJ, Pirgon A, Kanber B, Karanjia N, Brown G, Leach MO, Husband JE.Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging.Eur. Radiol. 2006;16:1898-1905.
105. Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, Husband JE.Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients.Am. J. Roentgenol. 2007;188:1001-1008.
106. Cui Y, Zhang XP, Sun YS, Tang L, Shen L.Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases.Radiology, 2008;248:894-900.
107. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR.Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI.Am. J. Roentgenol. 2008;191:285-289.
108. Braga L, Semelka RC.Magnetic resonance imaging features of focal liver lesions after intervention.Top. Magn. Reson. Imaging, 2005;16:99-106.
109. Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA.Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations.Acta Oncol. 2009;48:1034-1043.